

PRODUCT MONOGRAPH

PrMETHOTREXATE INJECTION, USP

Unpreserved

25 mg/mL methotrexate (as methotrexate sodium)

Sterile Solution

Intramuscular, intravenous, intra-arterial, intrathecal, and intracerebroventricular

Antimetabolite and Antirheumatic

Strides Pharma Canada Inc.
1565, Boul. Lionel-Boulet
Varenes, Quebec
J3X 1P7

Date of Revision:
October 14, 2021

Submission Control No.: 254503

TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE	3
CONTRAINDICATIONS.....	4
WARNINGS AND PRECAUTIONS	5
ADVERSE REACTIONS.....	13
DRUG INTERACTIONS	16
DOSAGE AND ADMINISTRATION	20
OVERDOSAGE.....	29
ACTION AND CLINICAL PHARMACOLOGY	29
STORAGE AND STABILITY	32
SPECIAL HANDLING INSTRUCTIONS.....	32
DOSAGE FORMS, COMPOSITION AND PACKAGING	33
PART II: SCIENTIFIC INFORMATION	34
PHARMACEUTICAL INFORMATION.....	34
DETAILED PHARMACOLOGY	35
TOXICOLOGY.....	36
REFERENCES.....	38
PART III: CONSUMER INFORMATION.....	43

Pr **METHOTREXATE INJECTION, USP**

Unpreserved

25 mg/mL methotrexate (as methotrexate sodium)

Sterile Solution

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Intramuscular, intravenous, intra-arterial, intrathecal, intracerebroventricular	25 mg/mL	<i>For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING section.</i>

INDICATIONS AND CLINICAL USE

Methotrexate Injection, USP is indicated for Neoplastic diseases:

- Choriocarcinoma: Methotrexate – as single chemotherapy or in combination with other drugs.
- Intermediate, or high-grade Non-Hodgkin's Lymphoma – as part of ProMACE-CytaBOM, ProMACE-MOPP, and Magrath protocols.
- Breast Cancer – as part of CMF (cyclophosphamide-methotrexate-fluorouracil) therapy.
- Acute Lymphoblastic Leukemia (ALL) – as maintenance therapy.
- Head and Neck Cancer – in combination with other chemotherapies.
- Gastric Cancer – palliative combination chemotherapy.
- Metastasis of unknown primary – as palliative combination chemotherapy.
- Osteogenic sarcoma (adjuvant) – high dose methotrexate with leucovorin rescue (HDMTX-LV)
- Bladder Cancer (advanced) – as part of the M-VAC Regimen.
- Leptomeningeal spread of malignancies (carcinomatosis/leukemia/lymphoma) as a single chemotherapy or alternating with Ara-C
- Burkitt's lymphoma
- Advanced stages of childhood lymphoma (III and IV, St. Jude's Childrens' Research Hospital Staging System).
- Advanced cases of mycosis fungoides (cutaneous T-cell lymphoma).

Methotrexate Injection, USP is indicated as a Disease Modifying Antirheumatic Drug (DMARD) in the following diseases where standard therapeutic interventions fail:

- Severe disabling psoriasis/psoriatic arthritis
- Severe disabling rheumatoid arthritis (RA)

- Severe disabling seronegative arthritides.

In the treatment of psoriasis, Methotrexate Injection USP should be restricted to severe recalcitrant, disabling psoriasis, which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established after dermatologic consultation.

Geriatrics (≥65 years of age):

The clinical pharmacology of methotrexate has not been well studied in older individuals. Due to diminished hepatic and renal function, as well as decreased folate stores in this population, relatively low doses should be considered, and these patients should be closely monitored for early signs of toxicity.

Pediatrics (<18 years of age):

Safety and effectiveness in pediatric patients have not been established, other than in cancer chemotherapy. Therefore, Methotrexate Injection USP should not be used as a DMARD in pediatric patients.

CONTRAINDICATIONS

Methotrexate Injection USP is contraindicated:

- In patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section.
- In patients with severe renal impairment including end stage renal disease with and without dialysis (see **WARNINGS AND PRECAUTIONS- Renal, Special populations and DOSAGE AND ADMINISTRATION- Special populations**).
- In pregnant patients with psoriasis or rheumatoid arthritis and should be used in the treatment of neoplastic diseases only when the potential benefit outweighs the risk to the fetus.
- In women of childbearing potential until pregnancy is excluded.
- In nursing mothers.
- In patients with psoriasis or rheumatoid arthritis with alcoholism, alcoholic liver disease or other chronic liver disease.
- In patients with psoriasis or rheumatoid arthritis who have overt or laboratory evidence of immunodeficiency syndromes.
- In patients with psoriasis or rheumatoid arthritis who have pre-existing blood dyscrasias, such as bone marrow hypoplasia, leucopenia, thrombocytopenia or significant anemia.
- With nitrous oxide anesthesia (see **WARNINGS AND PRECAUTIONS: Renal and DRUG INTERACTIONS: Drug-Drug Interactions**).

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

- Methotrexate Injection, USP should be used only by physicians whose knowledge and experience includes the use of antimetabolite therapy because of the possibility of serious toxic reactions (see WARNINGS AND PRECAUTIONS: General).
- Methotrexate has been reported to cause fetal death and/or congenital anomalies (see **Special Populations: Pregnant Women** section below). Therefore, use is contraindicated for women of childbearing potential until pregnancy is excluded and pregnant patients with psoriasis or rheumatoid arthritis (see **CONTRAINDICATIONS**).

General

Fatal toxicities related to inadvertent daily rather than weekly dosing have been reported, particularly in elderly patients. It should be emphasized to the patient that the recommended dose is taken weekly for rheumatoid arthritis and psoriasis, and that daily use of the weekly recommended dose has led to fatal toxicity.

Fatal toxicities related to intravenous dosing miscalculation have been reported. Special attention must be given to dose calculation.

Because of the possibility of serious toxic reactions (which can be fatal), Methotrexate Injection, USP should be used only in neoplastic diseases (as indicated), or in patients with severe, recalcitrant, disabling psoriasis or rheumatoid arthritis that are not adequately responsive to other forms of therapy. The patient should be informed by the physician of the risks involved and should be under a physician's constant supervision.

The use of methotrexate high-dose regimens recommended for osteosarcoma requires meticulous care (see **DOSAGE AND ADMINISTRATION**). High dosage regimens for other neoplastic diseases are investigational and a therapeutic advantage has not been established.

Toxic effects may be related in frequency and severity to dose or frequency of administration but have been seen at all doses. Because they can occur at any time during therapy, it is necessary to follow patients on Methotrexate Injection, USP closely. Most adverse reactions are reversible if detected early. When such reactions do occur, the drug should be reduced in dosage or discontinued and appropriate corrective measures should be taken. If necessary, this could include the use of leucovorin calcium and/or acute, intermittent hemodialysis with a high-flux dialyzer (see **OVERDOSAGE**). If Methotrexate Injection, USP therapy is re-instituted, it should be carried out with caution, with adequate consideration of further need for the drug and with increased alertness as to possible recurrence of toxicity.

Methotrexate may induce "tumour lysis syndrome" in patients with rapidly growing tumours. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication.

Methotrexate exits slowly from third space compartments (e.g., pleural effusions or ascites). This results in a prolonged terminal plasma half-life and unexpected toxicity. In patients with significant third space accumulations, it is advisable to evacuate the fluid before treatment and to monitor plasma methotrexate levels.

Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with non-steroidal anti-inflammatory drugs (NSAIDs) (see **DRUG INTERACTIONS**).

Bone marrow and mucosal toxicity depend on dose and duration of exposure of high levels ($>2 \times 10^{-8}$ mol/L (0.02 micromolar)) of methotrexate. Since the critical time factor has been defined for these organs as being 42 hours in humans, this has the following implications:

- when high doses of methotrexate are employed ($>1 \text{g/m}^2$), drug levels in serum should be monitored
- when drug levels exceeding (2×10^{-8} mol/L (0.02 micromolar)) for >42 hours may forecast significant toxicity
- when toxicity can be minimized by appropriate administration of Leucovorin Calcium
- when high-dose methotrexate (HDMTX) is employed, it is imperative to alkalinise the urine in order to prevent crystallisation of methotrexate and its 7-hydroxy metabolite in the urine, which may lead to acute renal failure.

Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.

Methotrexate Injection, USP should be used with extreme caution in the presence of debility.

The use of methotrexate high-dose regimens ($\geq 500 \text{ mg/m}^2$) recommended for osteosarcoma requires meticulous care. High-dosing regimens for other neoplastic diseases are investigational and a therapeutic advantage has not been established.

Drug Interactions with Proton Pump Inhibitors (PPI)

Use caution when administering high-dose methotrexate to patients receiving proton pump inhibitor (PPI) therapy. Case reports and published population pharmacokinetic studies suggest that concomitant use of some PPIs, such as omeprazole, esomeprazole, and pantoprazole, with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite hydromethotrexate, possibly leading to methotrexate toxicities. In two of these cases, delayed methotrexate elimination was observed when high-dose methotrexate was co-administered with PPIs, but was not observed when methotrexate was co-administered with ranitidine. However, no formal drug interaction studies of methotrexate with ranitidine have been conducted.

Carcinogenesis and Mutagenesis

Malignant lymphomas may occur in patients receiving low-dose methotrexate. These lymphomas may regress following withdrawal of methotrexate without requiring treatment. No controlled human data exist regarding the risk of neoplasia with methotrexate. Methotrexate has been evaluated in a number of animal studies for carcinogenic potential with inconclusive results. Although there is evidence that methotrexate causes chromosomal damage to animal somatic cells and human bone marrow cells, the clinical significance remains uncertain. Assessment of the carcinogenic potential of methotrexate is complicated by conflicting evidence of an increased risk of certain tumours in rheumatoid arthritis. Benefit should be weighed against this potential risk before using Methotrexate Injection, USP alone or in combination with other drugs, especially in children or young adults. (See **TOXICOLOGY**).

Gastrointestinal

If vomiting, diarrhea, or stomatitis occurs, resulting in dehydration, Methotrexate Injection, USP should be discontinued until recovery occurs. Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur. Methotrexate Injection, USP should be used with extreme caution in the presence of peptic ulcer disease or ulcerative colitis.

Use caution when administering high-dose methotrexate to patients receiving proton pump inhibitor (PPI) therapy as concomitant use of some PPIs, such as omeprazole, esomeprazole, and pantoprazole, with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite hydromethotrexate, possibly leading to methotrexate toxicities (see **DRUG INTERACTIONS: Drug-Drug Interactions**).

Hematologic

Methotrexate Injection, USP should be used with caution in patients with impaired bone marrow function and previous or concomitant wide field radiotherapy. Methotrexate may produce marked bone marrow depression with resultant anemia, aplastic anemia, pancytopenia, leucopenia, neutropenia, and/or thrombocytopenia. In controlled clinical trials in rheumatoid arthritis (n=128), leucopenia (WBC <3000/mm³) was seen in 2 patients, thrombocytopenia (platelets <100,000/mm³) in 6 patients, and pancytopenia in 2 patients.

The nadir of circulating leukocytes, neutrophils and platelets usually occurs between 5 and 13 days after an IV bolus dose (with recovery between 14 to 28 days). Leukocytes and neutrophils may occasionally show two depressions, the first occurring in 4-7 days and a second nadir after 12-21 days, followed by recovery. Clinical sequel such as fever, infections and hemorrhage from various sites may be expected.

In psoriasis and rheumatoid arthritis, Methotrexate Injection, USP should be stopped immediately if there is a significant drop in blood counts. In the treatment of neoplastic diseases, Methotrexate Injection, USP should be continued only if the potential benefit warrants the risk of severe myelosuppression. Patients with profound granulocytopenia and fever should be evaluated immediately and usually require parenteral broad-spectrum antibiotic therapy.

Hepatic/Biliary/Pancreatic

Methotrexate has the potential for acute (elevated transaminases) and chronic (fibrosis and cirrhosis) hepatotoxicity. Acutely, liver enzyme elevations are frequently seen after methotrexate

administration and are usually not a reason for modification of methotrexate therapy. Liver enzyme elevations are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. Persistent liver abnormalities, and/or decrease of serum albumin may be indicators of serious liver toxicity. Chronic toxicity is potentially fatal; it generally has occurred after prolonged use (generally two years or more) and after a total cumulative dose of at least 1.5 grams. Liver biopsy after sustained use often shows histologic changes, and fibrosis and cirrhosis have been reported; these latter lesions may not be preceded by symptoms or abnormal liver function tests in the psoriasis population. Periodic liver biopsies are usually recommended for psoriatic patients who are under long-term treatment. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in the rheumatoid arthritis population. In studies in psoriatic patients, hepatotoxicity appeared to be a function of total cumulative dose and appeared to be enhanced by alcoholism, obesity, diabetes and advanced age. An accurate incidence rate has not been determined; the rate of progression and reversibility of lesions is not known. Special caution is indicated in the presence of pre-existing liver damage or impaired hepatic function.

Methotrexate has caused reactivation or worsening of hepatitis B and C infections, in some cases resulting in death. Some cases of hepatitis B reactivation have occurred after discontinuation of methotrexate. Prior to treatment with Methotrexate Injection, USP, clinical and laboratory evaluation should be performed to evaluate preexisting hepatitis virus B and hepatitis virus C infection. Methotrexate Injection, USP is not recommended for patients with active or chronic hepatitis B or C infection.

In psoriasis, liver damage and function tests, including serum albumin and prothrombin time, should be performed several times prior to dosing, but are often normal in the face of developing fibrosis or cirrhosis. These lesions may be detectable only by biopsy. The usual recommendation is to obtain a liver biopsy: 1) before the start of therapy or shortly after initiation of therapy (4-8 weeks); 2) after a total cumulative dose of 1.5 grams; and 3) after each additional 1.0 to 1.5 grams. Moderate fibrosis or any cirrhosis normally leads to discontinuation of the drug; mild fibrosis normally suggests a repeat biopsy in 6 months. Milder histologic findings such as fatty change and low-grade portal inflammation are relatively common pre-therapy. Although these mild changes are usually not a reason to avoid or discontinue Methotrexate Injection, USP therapy, the drug should be used with caution.

Clinical experience with liver disease in rheumatoid arthritis is limited, but the same risk factors would be anticipated. Liver function tests are also usually not reliable predictors of histological changes in this population.

In rheumatoid arthritis, advanced age at first use of methotrexate and increasing duration of therapy have been reported as risk factors for hepatotoxicity. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in the rheumatoid population. Liver function tests should be performed at baseline and at 4-8 week intervals in patients receiving Methotrexate Injection, USP for rheumatoid arthritis. Pretreatment liver biopsy should be performed for patients with a history of excessive alcohol consumption, persistently abnormal baseline liver function test values, or chronic hepatitis B or C infection. During therapy, liver biopsy should be performed if there are persistent liver function test abnormalities, or there is a decrease in serum albumin below the normal range (in the setting of well controlled rheumatoid arthritis).

If the results of a liver biopsy show mild changes (Roenigk grades I, II, IIIa), Methotrexate Injection, USP may be continued and the patient monitored according to the recommendations listed above. Methotrexate Injection, USP should be discontinued in any patient who displays persistently abnormal liver function tests and refuses liver biopsy, or in any patient whose liver biopsy shows moderate to severe changes (Roenigk grade IIIb or IV).

There is a combined reported experience in 217 rheumatoid arthritis patients with liver biopsies both before and during treatment (after a cumulative dose of at least 1500 mg) and in 714 patients with a biopsy only during treatment. There are 64 (7%) cases of fibrosis and 1 (0.1%) case of cirrhosis. Of the 64 cases of fibrosis, 60 were deemed mild. The reticulin stain is more sensitive for early fibrosis and its use may increase these figures. It is unknown whether even longer use will increase these risks.

Immune

Methotrexate Injection, USP should be used with extreme caution in the presence of active infection, and is contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes (see **CONTRAINDICATIONS**).

Immunization may be ineffective when given during methotrexate therapy. Immunization with live virus vaccines is generally not recommended. Hypogammaglobulinemia has been reported rarely.

Neurologic

There have been reports of leukoencephalopathy following intravenous administration of methotrexate to patients who have had craniospinal irradiation. Serious neurotoxicity, frequently manifested as generalized or focal seizures, has been reported with unexpectedly increased frequency among pediatric patients with acute lymphoblastic leukemia who were treated with intravenous methotrexate (1 g/m²). Symptomatic patients were commonly noted to have leukoencephalopathy and/or microangiopathic calcifications on diagnostic imaging studies.

Chronic leukoencephalopathy has also been reported in patients with osteosarcoma who received repeated doses of high-dose methotrexate with leucovorin rescue even without cranial irradiation. There are also reports of leukoencephalopathy in patients who received low oral doses (4-8 mg/week) of methotrexate therapy for rheumatoid arthritis or psoriatic arthritis.

Discontinuation of Methotrexate Injection, USP does not always result in complete recovery.

A transient acute neurologic syndrome has been observed in patients treated with high dosage regimens. Manifestations of this neurologic disorder may include behavioural abnormalities, focal sensorimotor signs, including transient blindness and abnormal reflexes. The exact cause is unknown.

After the intrathecal use of methotrexate, the central nervous system toxicity which may occur can be classified as follows: chemical arachnoiditis manifested by such symptoms as headache, back pain, nuchal rigidity, and fever; paresis, usually transient, manifested by paraplegia associated with involvement with one or more spinal nerve roots; leukoencephalopathy manifested by confusion, irritability, somnolence, ataxia, dementia, and occasionally major

convulsions.

Intravenous administration of methotrexate may also result in acute encephalitis and acute encephalopathy with fatal outcome.

Cases of severe neurological adverse reactions that ranged from headache to paralysis, coma and stroke-like episodes have been reported mostly in juveniles and adolescents given methotrexate in combination with intravenous cytarabine.

Renal

Methotrexate is contraindicated in patients with severe renal impairment including end stage renal disease with and without dialysis (see **CONTRAINDICATIONS** and **DOSAGE AND ADMINISTRATION- Special populations**). Methotrexate therapy in patients with mild and moderate renal impairment should be undertaken with extreme caution, and at reduced dosages, because renal dysfunction will prolong methotrexate elimination. Methotrexate may cause renal damage that may lead to acute renal failure. High doses of methotrexate used in the treatment of osteosarcoma may cause renal damage leading to acute renal failure. Nephrotoxicity is due primarily to the precipitation of methotrexate and 7-hydroxymethotrexate in the renal tubules. Close attention to renal function including adequate hydration, urine alkalinization and measurement of serum methotrexate and creatinine levels are essential for safe administration.

Nephritis has been reported on co-administration with nitrous oxide anesthesia in rheumatoid arthritis patients (see **CONTRAINDICATIONS** and **DRUG INTERACTIONS: Drug-Drug Interactions**).

Respiratory

Methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis, is a potentially dangerous lesion which may occur at any time during therapy and which has been reported at low doses. It is not always fully reversible and fatalities have been reported. Cases of pleural effusion with or without interstitial pneumonitis have also been reported at any time during therapy at low doses. Pulmonary symptoms (especially a dry nonproductive cough) or a non-specific pneumonitis occurring during methotrexate therapy may be indicative of a potentially dangerous lesion and require interruption of treatment and careful investigation. Although clinically variable, the typical patient with methotrexate-induced lung disease presents with fever, cough, dyspnea, hypoxemia, and an infiltrate on chest X-ray; infection (including pneumonia) needs to be excluded. This lesion can occur at all dosages.

Potentially fatal opportunistic infections, especially *Pneumocystis carinii* pneumonia, may occur with methotrexate therapy. When a patient presents with pulmonary symptoms, the possibility of *Pneumocystis carinii* should be considered.

Pulmonary alveolar haemorrhage has been reported with methotrexate. This event may also be associated with vasculitis and other comorbidities. Prompt investigations should be considered when pulmonary alveolar hamorrhage is suspected to confirm the diagnosis.

Sexual Function/Reproduction

Methotrexate causes embryotoxicity, abortion, and fetal defects in humans. It has also been

reported to cause impairment of fertility, oligospermia and menstrual dysfunction in humans, during and for a short period after cessation of therapy (see **TOXICOLOGY**). The risk of effects on reproduction should be discussed with both male and female patients taking Methotrexate Injection, USP (see **TOXICOLOGY**).

Skin

Severe, occasionally fatal, dermatologic reactions, including toxic epidermal necrolysis (Lyell's Syndrome), Stevens-Johnson syndrome, exfoliative dermatitis, skin necrosis, and erythema multiforme, have been reported in children and adults, within days of oral, intramuscular or intravenous methotrexate administration. Reactions were noted after single or multiple, low, intermediate or high doses of methotrexate in patients with neoplastic diseases, rheumatoid arthritis or psoriasis. Recovery has been reported with discontinuation of therapy.

Lesions of psoriasis may be aggravated by concomitant exposure to ultraviolet radiation. Radiation dermatitis and sunburn may be "recalled" by the use of methotrexate.

Special Populations

Pregnant Women: Methotrexate Injection, USP is contraindicated in pregnant patients with psoriasis or rheumatoid arthritis (see **CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS: Serious Warnings and Precautions**) and should be used in the treatment of neoplastic diseases only when the potential benefit outweighs the risk to the fetus. Methotrexate has been reported to cause impairment of fertility, oligospermia and menstrual dysfunction in humans, during and for a short period after cessation of therapy. Methotrexate can cause fetal death, embryotoxicity, abortion, or teratogenic effects when administered to a pregnant woman.

Methotrexate Injection, USP is contraindicated in women of childbearing potential until pregnancy is excluded and should be fully counselled on the serious risk to the fetus should they become pregnant while undergoing treatment (see **CONTRAINDICATIONS**). Pregnancy should be avoided if either partner is receiving Methotrexate Injection, USP. The optimal time interval between the cessation of methotrexate treatment of either partner and pregnancy has not been clearly established. Published literature recommendations for time intervals vary from 3 months to one year. The risk of effects on reproduction should be discussed with both male and female patients taking Methotrexate Injection, USP.

Nursing Women: Methotrexate Injection, USP is contraindicated in nursing mothers because of the potential for serious adverse reactions from methotrexate in breast-fed infants.

Pediatrics (<18 years of age): Safety and effectiveness in pediatric patients have not been established, other than in cancer chemotherapy.

Overdose by intravenous miscalculation of dosage (particularly in juveniles) have occurred. Special attention must be given to dose calculation.

Geriatrics (≥65 years of age): The clinical pharmacology of methotrexate has not been well studied in older individuals. Due to diminished hepatic and renal function, as well as decreased folate stores in this population, relatively low doses should be considered. Fatal toxicities related to inadvertent daily rather than weekly dosing have been reported, particularly in elderly

patients. Elderly patients should be closely monitored for early signs of hepatic, bone marrow and renal toxicity.

Renal Impairment: Methotrexate Injection, USP is contraindicated in patients with severe renal impairment (see **CONTRAINDICATIONS** and **DOSAGE AND ADMINISTRATION-Special populations**).

Monitoring and Laboratory Tests

General: Patients undergoing Methotrexate Injection, USP therapy should be informed of the early signs and symptoms of toxicity and closely monitored so that toxic effects are detected promptly. Serum methotrexate level monitoring can significantly reduce toxicity and mortality by allowing the adjustment of methotrexate dosing and the implementation of appropriate rescue measures. Patients subject to the following conditions are predisposed to developing elevated or prolonged methotrexate levels and benefit from routine monitoring of levels: e.g., pleural effusion, ascites, gastrointestinal tract obstruction, previous cisplatin therapy, dehydration, aciduria, and impaired renal function. Some patients may have delayed methotrexate clearance in the absence of these features. It is important that patients be identified within 48 hours since methotrexate toxicity may not be reversible if adequate leucovorin rescue is delayed for more than 42 to 48 hours.

Monitoring of methotrexate concentrations should include determination of a methotrexate level at 24, 48, or 72 hours, and assessment of the rate of decline in methotrexate concentrations (to determine how long to continue leucovorin rescue).

Baseline assessment should include a complete blood count with differential and platelet counts, hepatic enzymes, renal function tests, and a chest X-ray. During initial or changing doses, or during periods of increased risk of elevated methotrexate blood levels (e.g., dehydration), more frequent monitoring may also be indicated.

During therapy of rheumatoid arthritis and psoriasis, monitor:

- **Hematologic:** Patients should have their blood tests checked at least monthly.
- **Hepatic:** Liver biopsies prior to Methotrexate Injection, USP therapy are not indicated routinely. Liver function tests should be determined prior to the initiation of therapy with Methotrexate Injection, USP and they should be monitored every 1 to 2 months. A relationship between abnormal liver function tests and fibrosis or cirrhosis of the liver has not been established. Transient liver function test abnormalities are observed frequently after methotrexate administration and are usually not cause for modification of Methotrexate Injection, USP therapy. Persistent liver function test abnormalities just prior to dosing and/or depression of serum albumin may be indicators of serious liver toxicity and require evaluation.
- **Renal:** Renal function should be monitored every 1 to 2 months.

- **Respiratory:** Pulmonary function tests may be useful if methotrexate-induced lung disease (e.g. interstitial pneumonitis) is suspected, especially if baseline measurements are available.

During therapy of neoplastic disease:

More frequent monitoring is usually indicated during antineoplastic therapy for hematologic, hepatic, renal and respiratory.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

In general, the incidence and severity of acute side effects are related to dose, frequency of administration, and the duration of the exposure to significant blood levels of methotrexate to the target organs. The most serious reactions are discussed under **WARNINGS AND PRECAUTIONS** section. The most frequently reported adverse reactions include ulcerative stomatitis, leucopenia, nausea, and abdominal distress. Other frequently reported adverse effects are malaise, undue fatigue, chills and fever, dizziness and decreased resistance to infection. Ulcerations of the oral mucosa are usually the earliest signs of toxicity.

Adverse Drug Reactions by Organ System

Blood and lymphatic system disorders:	Leucopenia, anemia, aplastic anemia, thrombopenia, pancytopenia, agranulocytosis, lymphadenopathy and lymphoproliferative disorders (including reversible), neutropenia and eosinophilia have also been observed.
Cardiac disorders:	Pericarditis and pericardial effusion (damage to heart, rarely).
Eye disorders:	Conjunctivitis, blurred vision, serious visual changes of unknown etiology, and transient blindness/vision loss.
Gastrointestinal disorders:	Gingivitis, stomatitis, enteritis, anorexia, nausea, vomiting, diarrhea, hematemesis, melena, gastrointestinal ulceration and bleeding, pancreatitis, intestinal perforation, non-infectious peritonitis, glossitis.
General disorders and administration site conditions:	Anaphylactoid reactions, vasculitis, fever, conjunctivitis, infection, sepsis, nodulosis, hypogammaglobulinaemia, and sudden death.
Hepatobiliary disorders:	Hepatotoxicity, acute hepatitis, chronic fibrosis and cirrhosis, decrease in serum albumin, liver enzyme elevations, hepatic failure.
Infection:	Other reported infections included nocardiosis, histoplasmosis, cryptococcosis, and disseminated <i>H. simplex</i> , cytomegalovirus infection, including cytomegaloviral pneumonia.

Metabolism and nutrition disorders:	Diabetes mellitus.
Musculoskeletal, connective tissue, and bone disorders:	Stress fractures, soft tissue necrosis, osteonecrosis, arthralgia, myalgia and osteoporosis.
Neoplasms benign, malignant and unspecified (including cysts and polyps):	Tumour lysis syndrome. Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate, and thus may not require cytotoxic treatment. Discontinue Methotrexate Injection, USP first and, if the lymphoma does not regress, appropriate treatment should be instituted.
Nervous system:	Cerebrospinal fluid pressure increased, neurotoxicity, arachnoiditis, paresthesia, headache, dizziness, drowsiness, speech impediment including dysarthria and aphasia; hemiparesis, paresis and convulsions. Following low doses, there have been occasional reports of transient subtle cognitive dysfunction, mood alteration, or unusual cranial sensations, leukoencephalopathy, or encephalopathy.
Renal and urinary disorders:	Renal failure, severe nephropathy or renal failure, azotemia, dysuria, cystitis, hematuria, urogenital dysfunction. Proteinuria has also been observed.
Reproductive system and breast disorders:	Defective oogenesis or spermatogenesis, transient oligospermia, menstrual dysfunction, vaginal discharge and gynecomastia; infertility, abortion, fetal defects, loss of libido/impotence.
Respiratory, thoracic and mediastinal disorders:	Pneumonia, interstitial alveolitis/pneumonitis often associated with eosinophilia, pulmonary fibrosis, Pneumocystis carinii pneumonia, pleural effusion. Dyspnea, chest pain, hypoxia, respiratory fibrosis, pharyngitis, and chronic interstitial obstructive pulmonary disease, alveolitis and pulmonary alveolar haemorrhage have occasionally occurred.
Skin disorders:	Erythema, pruritus, photosensitisation, petechiae, loss of hair, skin necrosis, exfoliative dermatitis, painful erosion of psoriatic plaques, herpes zoster, vasculitis, urticaria, pigmentary changes, acne, ecchymosis, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), furunculosis and telangiectasia. Drug reaction with eosinophilia and systemic symptoms.
Vascular disorders:	Hypotension, and thromboembolic events (including arterial thrombosis, cerebral thrombosis, deep vein thrombosis, retinal vein thrombosis, thrombophlebitis, and pulmonary embolus), vasculitis.

Adverse Reactions Reported in Rheumatoid Arthritis:

- Alopecia (common)

- Diarrhea (common)
- Dizziness (common)
- Elevated liver enzymes (very common)
- Leucopenia (common)
- Nausea/vomiting (very common)
- Pancytopenia (common)
- Rash/pruritus/dermatitis (common)
- Stomatitis (common)
- Thrombocytopenia (common)

Adverse Reactions in Psoriasis:

The adverse reaction rates reported are very similar to those in the rheumatoid arthritis studies. Rarely, painful psoriatic plaque erosions may appear.

Abnormal Hematologic and Clinical Chemistry Findings

See **WARNINGS AND PRECAUTIONS: Monitoring and Laboratory Tests** section.

Post-Market Adverse Drug Reactions

Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following adverse events have also been reported during post-marketing experience with methotrexate:

System Organ Class	Adverse Reaction
Infections and Infestations	Infections (including fatal sepsis); Pneumonia; <i>Pneumocystis carinii</i> pneumonia; Nocardiosis; Histoplasmosis; Cryptococcosis; Herpes zoster; <i>H. simplex</i> hepatitis; Disseminated <i>H. simplex</i> ; Cytomegalovirus infection (including cytomegaloviral pneumonia); Reactivation of hepatitis B infection; Worsening of hepatitis C infection
Blood and Lymphatic System Disorders	Agranulocytosis; Pancytopenia; Leukopenia; Neutropenia; Lymphadenopathy and lymphoproliferative disorders (including reversible); Eosinophilia; Anemia megaloblastic; Renal vein thrombosis; Lymphoma; Aplastic anemia; Hypogammaglobulinemia
Nervous System Disorders	CSF pressure increased; Neurotoxicity; Arachnoiditis; Paraplegia; Stupor; Ataxia; Dementia; Dizziness; Paresthesia
Respiratory, Thoracic and Mediastinal Disorders	Chronic interstitial pulmonary disease; Alveolitis; Dyspnea; Chest pain; Hypoxia;

System Organ Class	Adverse Reaction
	Cough; Plural effusion
Gastrointestinal Disorders	Intestinal perforation; Noninfectious peritonitis; Glossitis; Nausea; Pancreatitis
Hepatobiliary Disorders	Hepatic failure
Skin and Subcutaneous Tissue Disorders	Drug reaction with eosinophilia and systemic symptoms; Dermatitis; Petechiae
Musculoskeletal, Connective Tissue and Bone Disorders	Osteonecrosis
Renal and Urinary Disorders	Proteinuria
Pregnancy, Puerperium and Perinatal Conditions	Fetal death, Abortion
Reproductive System and Breast Disorders	Urogenital dysfunction
General Disorders and Administration Site Conditions	Pyrexia; Chills; Malaise; Fatigue; Anaphylactic reactions
Endocrine Disorders	Diabetes
Ophthalmologic Disorders	Transient blindness/vision loss

DRUG INTERACTIONS

Serious Drug Interactions

The use of nitrous oxide anesthesia with methotrexate is contraindicated (see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS - Renal and DRUG INTERACTIONS - Drug-Drug Interactions).

Overview

Methotrexate competes with reduced folates for active transport across cell membranes by means of a single carrier-mediated active transport process. Impaired renal function, as well as concurrent use of drugs such as weak organic acids that undergo tubular secretion, can markedly increase methotrexate serum levels. Laboratory studies demonstrate that methotrexate may be displaced from plasma albumin by various compounds including sulfonamides, salicylates, tetracyclines, chloramphenicol and phenytoin.

Drug-Drug Interactions

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

NSAIDs should not be administered prior to or concomitantly with the high doses of methotrexate. Concomitant administration of NSAIDs with high-dose methotrexate therapy has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic (including bone marrow suppression and aplastic anemia) and gastrointestinal toxicity. These drugs have been reported to reduce the tubular secretion of methotrexate, in an animal model, and may enhance its toxicity by increasing methotrexate levels.

Caution should be used when NSAIDs and salicylates are administered concomitantly with lower doses of Methotrexate Injection, USP. In treating rheumatoid arthritis with Methotrexate, the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Despite the potential interactions, studies of methotrexate in patients with rheumatoid arthritis have usually included concurrent use of constant dosage regimens of

NSAIDs without apparent problems. It should be appreciated however, that the doses used in rheumatoid arthritis (7.5 to 15 mg/week) are somewhat lower than those used in psoriasis and that larger doses could lead to toxicity.

Disease Modifying Antirheumatic drugs (DMARDs)

Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, or sulfasalazine has not been studied and may increase the incidence of adverse effects.

Amiodarone

Amiodarone administration to patients receiving methotrexate treatment for psoriasis has induced ulcerated skin lesions.

L-asparaginase

The administration of L-asparaginase has been reported to antagonize the effect of methotrexate.

Diuretics

Bone marrow suppression and decreased folate levels have been described in the concomitant administration of triamterene and methotrexate.

Leflunomide

Methotrexate in combination with leflunomide may increase the risk of pancytopenia.

Drugs Highly Bound to Plasma Proteins

Methotrexate is partially bound to serum albumin, and toxicity may be increased because of displacement by other highly bound drugs, such as sulfonyleureas, aminobenzoic acid, salicylates, phenylbutazone, phenytoin, sulfonamides, some antibiotics such as penicillins, tetracycline, pristinamycin, probenecid, and chloramphenicol.

Packed Red Blood Cells

Care should be exercised whenever packed red blood cells and Methotrexate Injection, USP are given concurrently. Patients receiving 24-hr methotrexate infusion and subsequent transfusions have showed enhanced toxicity probably resulting from prolonged high serum-Methotrexate concentrations.

Probenecid

Renal tubular transport is also diminished by probenecid; use of Methotrexate Injection, USP with this drug should be carefully monitored.

Proton Pump Inhibitors

Use caution when administering high-dose methotrexate to patients receiving proton pump inhibitor (PPI) therapy. Concomitant use of PPIs and high-dose methotrexate should be avoided especially in patients with renal impairment. Case reports and published population pharmacokinetic studies suggest that concomitant use of some PPIs, such as omeprazole,

esomeprazole, and pantoprazole, with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite hydromethotrexate, possibly leading to methotrexate toxicities. In two of these cases, delayed methotrexate elimination was observed when high-dose methotrexate was co-administered with PPIs, but was not observed when methotrexate was co-administered with ranitidine. However, no formal drug interaction studies of methotrexate with ranitidine have been conducted.

Psoralen Plus Ultraviolet Light (PUVA) Therapy

Skin cancer has been reported in patients with psoriasis or mycosis fungoides (a cutaneous T-cell lymphoma) receiving a concomitant treatment with methotrexate plus PUVA therapy.

Nephrotoxic Drugs

In the treatment of patients with osteosarcoma, caution must be exercised if high-dose methotrexate is administered in combination with a potentially nephrotoxic chemotherapeutic agent (e.g., cisplatin). Methotrexate clearance is decreased by cisplatin.

Although not documented, other nephrotoxic drugs such as aminoglycosides, Amphotericin B and Cyclosporin could theoretically increase methotrexate toxicity by decreasing its elimination.

Nitrous Oxide

The use of nitrous oxide anesthesia potentiates the effect of methotrexate on folate metabolism, yielding increased toxicity such as severe, unpredictable myelosuppression, stomatitis, neurotoxicity (with intrathecal administration of methotrexate) and nephritis (see **CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS: Renal**). In case of accidental co-administration, this effect can be reduced by the use of leucovorin rescue.

Penicillins and Sulfonamides

Penicillins and sulfonamides may reduce the renal clearance of methotrexate; hematologic and gastrointestinal toxicity have been observed in combination with methotrexate. Use of Methotrexate Injection, USP with penicillins should be carefully monitored.

Ciprofloxacin

Renal tubular transport is diminished by ciprofloxacin; use of Methotrexate Injection, USP with this drug should be carefully monitored.

Oral Antibiotics

Oral antibiotics such as tetracycline, chloramphenicol, and nonabsorbable broad spectrum antibiotics, may decrease intestinal absorption of methotrexate or interfere with the enterohepatic circulation by inhibiting bowel flora and suppressing metabolism of the drug by bacteria. For example: Neomycin, Polymyxin B, Nystatin and Vancomycin decrease methotrexate absorption, whereas Kanamycin increases methotrexate absorption.

Trimethoprim/sulfamethoxazole has been reported rarely to increase bone marrow suppression in patients receiving methotrexate, probably by decreased tubular secretion and/or an additive antifolate effect. Concurrent use of the anti-protozoal *pyrimethamine* may increase the toxic

effects of methotrexate because of an additive antifolate effect.

Theophylline

Methotrexate may decrease the clearance of theophylline; theophylline levels should be monitored when used concurrently with Methotrexate Injection, USP.

Mercaptopurine

Methotrexate increases the plasma levels of mercaptopurine. Combination of Methotrexate Injection, USP and mercaptopurine may therefore require dose adjustment.

Vitamins

Vitamin preparations containing folic acid or its derivatives may decrease responses to methotrexate. Preliminary animal and human studies have shown that small quantities of intravenously administered leucovorin enter the cerebrospinal fluid primarily as 5-methyl tetrahydrofolate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.

However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.

In patients with rheumatoid arthritis or psoriasis, folic acid or folinic acid may reduce methotrexate toxicities such as gastrointestinal symptoms, stomatitis, alopecia, and elevated liver enzymes.

Before taking a folate supplement, it is advisable to check B₁₂ levels, particularly in adults over the age of 50, since folate administration can mask symptoms of B₁₂ deficiency.

Folate deficiency states may increase methotrexate toxicity.

Radiotherapy

Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.

Hepatotoxins

The potential for increased hepatotoxicity when methotrexate is administered with other hepatotoxic agents has not been evaluated. However, hepatotoxicity has been reported in such cases. Therefore, patients receiving concomitant therapy with Methotrexate Injection, USP and other potential hepatotoxic agents (e.g., leflunomide, azathioprine, sulfasalazine, retinoids) should be closely monitored for possible increased risk of hepatotoxicity.

Cytarabine and other cytotoxic agents

Methotrexate given concomitantly with IV cytarabine may increase the risk of severe neurologic adverse events such as headache, paralysis, coma and stroke-like episodes (see **WARNINGS AND PRECAUTIONS: Neurologic**).

Combined use of methotrexate with other cytotoxic agents has not been studied and may increase the incidence of adverse effects.

Drug-Herb Interactions

The effects of herbal products on the pharmacokinetics of methotrexate have not been studied.

Drug-Laboratory Interactions

Interactions with laboratory tests have not been established.

Drug-Lifestyle Interactions

Use of alcohol with Methotrexate Injection, USP is contraindicated (see **CONTRAINDICATIONS**). The effects of smoking, on the pharmacokinetics of methotrexate have not been specifically studied.

Some of the effects (e.g., dizziness and fatigue) may have an influence on the ability to drive or operate machinery.

DOSAGE AND ADMINISTRATION

Dosing Considerations

Neoplastic Diseases:

- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
- Methotrexate Injection, USP without preservative may be given by the intramuscular, intravenous (as a bolus), intra-arterial, intrathecal or intracerebroventricular (via Ommaya reservoir into the CNS) routes.
- Methotrexate Injection, USP may only be administered by physicians experienced in the treatment of neoplasia. Typical dosages reported in the literature for the following malignancies are listed in the following section.

Psoriasis and Rheumatoid Arthritis:

- The patient should be fully informed of the risks involved and should be under constant supervision of the physician (see **WARNINGS AND PRECAUTIONS**).
- All dosage schedules should be continually tailored to the individual patient. An initial test dose may be given prior to the regular dosing schedule to detect any extreme sensitivity to adverse effects (see **ADVERSE REACTIONS**). Maximal myelosuppression usually occurs in seven to ten days.
- Both the physician and pharmacist should emphasize to the patient that the recommended dose is taken weekly in rheumatoid arthritis and psoriasis, and that mistaken daily use of the recommended dose has led to fatal toxicity.

Recommended Dose and Dosage Adjustments

Breast Cancer: The initial doses of CMF will be cyclophosphamide 100 mg/m² p.o. days 1 through 14, methotrexate 40 mg/m² IV day 1, 8, and 5 -Fluorouracil 600 mg/m² IV day 1, 8.

Cycle length will be 28 days ("2 weeks-on, 2 weeks-off"). In patients over 60 years of age, the dosage of methotrexate will be 30 mg/m² IV day 1, 8. If total bilirubin exceeds 1.5 mg/dL, decrease the dose of methotrexate only by 50%.

Bladder Cancer: Typical dosage regimens for bladder cancer are the CMV Regimen and the "M-VAC Regimen" which are represented in the following tables.

Table 1 - CMV Regimen*

Drugs**	Days		
	1	2	8¶
Cisplatin‡	-	100	-
Vinblastine	4	-	4
Methotrexate***	30	-	30

* All doses in mg/m² with cycles repeated on day 22.

**Patients >70 years old receive 80% of all doses; if vomiting persists to day 8, no drug is given.

‡For each cycle, adjust cisplatin to 100% for Ccr >60 mL/min; 50% of dose for Ccr 50-60 mL/min; none for Ccr <50 mL/min.

***No drug for a decrease on day 8 of >30 mL/min compared to day 1 or Ccr <50 mL/min or Cr >1.8 mg/dL.

¶ Major dose modifications for both drugs depending on myelosuppression.

Table 2 - M-VAC Regimen*

Drugs	Days			
	1	2	15	22***
Methotrexate	30	-	30	30
Vinblastine	-	3	3	3
Doxorubicin	-	30**	-	-
Cisplatin	-	70	-	-

* All doses in mg/m² with cycles repeated every 28-32 days.

**Patients having prior pelvic irradiation equivalent to >2500 rad in 5 days, reduce the dose of doxorubicin 15 mg/m².

***No doses given when the WBC <2500 cells/mm³, platelets >100,000 cells/mm³, or mucositis present.

Head and Neck Cancer: Methotrexate remains the standard of therapy for patients with recurrent or metastatic disease. It has been given in a wide variety of doses and schedules (a few of which are represented in the table below).

Table 3 - Methotrexate Schedule**

0.8 mg/kg every 4 days IV
25 - 50 mg every 4 to 7 days
60 mg/m ² weekly IV or 40 mg/m ² biweekly IV
40 - 60 mg/m ² weekly IV
80 mg/m ² for 30 h every 2 wk with escalation to toxicity
40 mg/m ² weekly IV
40-200 mg/m ² IV on days 1, 4 weekly; leucovorin on days 2,5
60 mg/m ² IV weekly

** excerpt from Devita, et al: *CANCER 3rd Ed, p. 496*

For palliation of patients with advanced, incurable disease and acceptable renal function, it is appropriate to begin intravenous methotrexate with weekly doses of 40-50 mg/m² or biweekly

doses of 15 to 20 mg/m² and escalate the dose in weekly increments until either mild toxicity or therapeutic response is achieved.

Gastric Cancer: A regimen used in a clinical trial in Belgium in patients with resectable gastric cancer follows: methotrexate (1.5 g/m² IV day 1) + 5-Fluorouracil (1.5 g/m² IV) + Leucovorin (15 mg/m² orally or IV every 6 hours for 72 hours) + Adriamycin (30 mg/m² IV, day 15). The schedule is repeated on day 29 for 6 cycles.

Choriocarcinoma and similar trophoblastic diseases: Methotrexate is administered intramuscularly in doses of 15 to 30 mg daily for a 5-day course. Such courses are usually repeated for 3 to 5 times as required, with rest periods of one or more weeks interposed between courses, until any manifesting toxic symptoms subside. The effectiveness of therapy is ordinarily evaluated by 24-hour quantitative analysis of urinary chorionic gonadotropin hormone (beta-HCG), which should return to normal or less than 50 IU/24 hr usually after the third or fourth course and usually be followed by a complete resolution of measurable lesions in 4 to 6 weeks. One to two courses of methotrexate after normalization of beta-HCG are usually recommended. Before each course of the drug, careful clinical assessment is essential. Cyclic combination therapy of methotrexate with other antitumour drugs has been reported as being useful.

Since hydatidiform mole may precede choriocarcinoma, prophylactic chemotherapy with methotrexate has been recommended.

Chorioadenoma destruens is considered to be an invasive form of hydatidiform mole. Methotrexate is administered in these disease states in doses similar to those recommended for choriocarcinoma.

Lymphomas: In Burkitt's tumour, Stages I-II, methotrexate has produced prolonged remissions in some cases. In Stage III, methotrexate is commonly given concomitantly with other antitumour agents. Treatment in all stages usually consists of several courses of the drug interposed with 7 to 10 day rest periods.

Lymphosarcomas in Stage III may respond to combined drug therapy with methotrexate given in doses of 0.625 to 2.5 mg/kg daily.

The treatment of choice for localized histologically aggressive lymphoma is primary combination chemotherapy with or without involved-field radiation therapy. Frequently used regimens for intermediate, or high grade NHL that include methotrexate include groups: the ProMACE/MOPP, ProMACE-CytaBOM, Magrath Protocols. Represented in the table below for example, is the ProMACE-CytaBOM Regimen.

Table 4 – ProMACE CytaBOM Regimen

ProMACE-CytaBOM	Day 1	Day 8	Day 14	Days 15-21
Cyclophosphamide 650 mg/m ² I.V.	x			No therapy
Doxorubicin 25 mg/m ² I.V.	x			
Etoposide 120 mg/m ² I.V.	x			
Cytarabine 300 mg/m ² I.V.		x		

ProMACE-CytaBOM	Day 1	Day 8	Day 14	Days 15-21
Bleomycin 5 mg/m ² I.V.		x		
Vincristine 1.4 mg/m ² I.V.		x		
Methotrexate 120 mg/m ² I.V.		x with leucovorin rescue		
Prednisone 60 mg/m ² PO	x-----			x
Co-trimoxazole 2 PO bid throughout 6 cycles of therapy				

In early stage childhood non-Hodgkin's lymphoma, methotrexate is used effectively in combination chemotherapy regimens.

Mycosis Fungoides (cutaneous T-cell lymphoma): Therapy with methotrexate appears to produce clinical responses in up to 50% of patients treated, but chemotherapy is not curative. Dose levels of drug and adjustment of dose regimen by reduction or cessation of drug are guided by patient response and hematologic monitoring. Methotrexate has also been given intramuscularly in doses of 50 mg once weekly or 25 mg of methotrexate twice weekly.

Leukemia: Acute lymphoblastic leukemia (ALL) in children and young adolescents is the most responsive to present day chemotherapy. In young adults and older patients, clinical remission is more difficult to obtain and early relapse is more common.

Methotrexate alone or in combination with steroids was used initially for induction of remission in ALL. More recently corticosteroid therapy, in combination with other antileukemic drugs or in cyclic combinations with methotrexate included, has appeared to produce rapid and effective remissions. When used for induction, methotrexate in doses of 3.3 mg/m² in combination with 60 mg/m² of prednisone, given daily, produced remissions in 50% of patients treated, usually within a period of 4 to 6 weeks. Methotrexate in combination with other agents appears to be the drug of choice for securing maintenance of drug-induced remissions. When remission is achieved and supportive care has produced general clinical improvement, maintenance therapy is initiated, as follows: methotrexate is administered twice weekly intramuscularly in total weekly doses of 30 mg/m². It has also been given in doses of 2.5 mg/kg intravenously every 14 days. If and when relapse does occur, re-induction of remission can again usually be obtained by repeating the initial induction regimen.

A variety of combination chemotherapy regimens have been used for both induction and maintenance therapy in ALL.

Meningeal Leukemia:

In the treatment or prophylaxis of meningeal leukemia, methotrexate must be administered intrathecally.

For intrathecal administration, preservative free methotrexate is diluted to a concentration of 1 mg/mL in an appropriate sterile, preservative free medium such as 0.9% Sodium Chloride Injection, USP.

The cerebrospinal fluid volume is dependent on age and not on body surface area. The CSF is at 40% of the adult volume at birth and reaches the adult volume in several years.

Intrathecal methotrexate administration at a dose of 12 mg/m² (maximum 15 mg) has been

reported to result in low CSF methotrexate concentrations and reduced efficacy in children and high concentrations and neurotoxicity in adults.

The following dosage regimen is based on age instead of body surface area:

Age (years)	Dose (mg)
<1	6
1	8
2	10
3 or older	12

In one study in patients under the age of 40, this dosage regimen appeared to result in more consistent CSF methotrexate concentrations and less neurotoxicity. Another study in children with acute lymphocytic leukemia compared this regimen to a dose of 12 mg/m² (maximum 15 mg), a significant reduction in the rate of CNS relapse was observed in the group whose dose was based on age.

Because the CSF volume and turnover may decrease with age, a dose reduction may be indicated in elderly patients.

For the treatment of meningeal leukemia, intrathecal methotrexate may be given at intervals of 2 to 5 days. However, administration at intervals of less than 1 week may result in increased subacute toxicity. Methotrexate is administered until the cell count of the cerebrospinal fluid returns to normal. At this point one additional dose is advisable. For prophylaxis against meningeal leukemia, the dosage is the same as for treatment except for the intervals of administration. On this subject, it is advisable for the physician to consult the medical literature.

Untoward side effects may occur with any given intrathecal injection and are commonly neurological in character. Large doses may cause convulsions. Methotrexate given by the intrathecal route appears significantly in the systemic circulation and may cause systemic methotrexate toxicity. Therefore, systemic antileukemic therapy with the drug should be appropriately adjusted, reduced, or discontinued. Focal leukemic involvement of the central nervous system may not respond to intrathecal chemotherapy and is best treated with radiotherapy.

Leptomeningeal Carcinomatosis:

Intrathecal administration of methotrexate as a single-drug or in combination regimens, is the most common therapy for carcinomatous leptomeningitis.

Treatment is optimally administered through an Ommaya reservoir and is usually started with methotrexate (10 mg/m²) given twice weekly until the cerebrospinal fluid cytology becomes negative. The treatment regimen is gradually decreased, first to a weekly course, and eventually to a single administration every two months.

Osteosarcoma: An effective adjuvant chemotherapy regimen requires the administration of several cytotoxic chemotherapeutic agents. In addition to high-dose methotrexate with leucovorin rescue, these agents may include doxorubicin, cisplatin, and the combination of bleomycin, cyclophosphamide and dactinomycin (BCD) in the doses and schedule shown in the

table below. The starting dose for high-dose Methotrexate treatment is 12 grams/m². If this dose is not sufficient to produce a peak serum methotrexate concentration of 1,000 micromolar (10⁻³mol/L) at the end of the methotrexate infusion, the dose may be escalated to 15 grams/m² in subsequent treatments. If the patient is vomiting or is unable to tolerate oral medication, leucovorin is given IV or IM at the same dose and schedule.

Drug*	Dose*	Treatment Week After Surgery
Methotrexate	12 g/m ² IV as 4 hour infusion (starting dose)	4,5,6,7,11,12,15,16,29,30,44,45
Leucovorin	15 mg orally every six hours for 10 doses starting at 24 hours after start of methotrexate infusion.	
Doxorubicin** as a single drug	30 mg/m ² /day IVx3 days	8,17
Doxorubicin**	50 mg/m ² IV	20,23,33,36
Cisplatin**	100 mg/m ² IV	20,23,33,36
Bleomycin**	15 units/m ² IV x 2 days	2,13,26,39,42
Cyclophosphamide**	600 mg/m ² IV x 2 days	2,13,26,39,42
Dactinomycin**	0.6 mg/m ² IV x 2 days	2,13,26,39,42

* Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. *N Engl J of Med* 1986; 314(No.25):1600-1606.

** See each respective package insert for full prescribing information. Dosage modifications may be necessary because of drug-induced toxicity.

When these higher doses of methotrexate are to be administered, the following safety guidelines should be closely observed.

GUIDELINES FOR METHOTREXATE THERAPY WITH LEUCOVORIN RESCUE

1. Administration of Methotrexate Injection, USP should be delayed until recovery if:
 - The WBC count is less than 1500/microliter
 - The neutrophil count is less than 200/microliter
 - The platelet count is less than 75,000/microliter
 - The serum bilirubin level is greater than 1.2 mg/dL
 - The SGPT level is greater than 450 U
 - Mucositis is present, until there is evidence of healing
 - Persistent pleural effusion is present; this should be drained dry prior to infusion.
2. Adequate renal function must be documented.
 - a) Serum creatinine must be normal, and creatinine clearance must be greater than 60 mL/min, before initiation of therapy.
 - b) Serum creatinine must be measured prior to each subsequent course of therapy. If serum creatinine has increased by 50% or more compared to a prior value, the creatinine clearance must be measured and documented to be greater than 60 mL/min (even if the serum creatinine is still within the normal range).
3. Patients must be well hydrated, and must be treated with sodium bicarbonate for urinary alkalization.
 - a) Administer 1,000 mL/m² of intravenous fluid over 6 hours prior to initiation of the Methotrexate Injection, USP infusion. Continue hydration at 125 mL/m²/hr (3

liters/m²/day) during the Methotrexate Injection, USP infusion, and for 2 days after the infusion has been completed.

- b) Alkalinize urine to maintain pH above 7.0 during Methotrexate Injection, USP infusion and leucovorin calcium therapy. This can be accomplished by the administration of sodium bicarbonate orally or by incorporation into a separate intravenous solution.
4. Repeat serum creatinine and serum methotrexate 24 hours after starting Methotrexate Injection, USP and at least once daily until the methotrexate level is below 5×10^{-8} mol/L (0.05 micromolar).
 5. The table below provides guidelines for leucovorin calcium dosage based upon serum methotrexate levels (See table below).

Patients who experience delayed early methotrexate elimination are likely to develop non-reversible oliguric renal failure. In addition to appropriate leucovorin therapy, these patients require continuing hydration and urinary alkalinization, and close monitoring of fluid and electrolyte status, until the serum methotrexate level has fallen to below 0.05 micromolar and the renal failure has resolved. If necessary, acute, intermittent hemodialysis with a high-flux dialyzer may also be beneficial in these patients.

6. Some patients will have abnormalities in methotrexate elimination, or abnormalities in renal function following methotrexate administration, which are significant but less severe than the abnormalities described in the table below. These abnormalities may or may not be associated with significant clinical toxicity. If significant clinical toxicity is observed, leucovorin rescue should be extended for an additional 24 hours (total 14 doses over 84 hours) in subsequent courses of therapy. The possibility that the patient is taking other medications which interact with Methotrexate Injection, USP (e.g., medications which may interfere with methotrexate binding to serum albumin, or elimination) should always be reconsidered when laboratory abnormalities or clinical toxicities are observed.

LEUCOVORIN RESCUE SCHEDULES FOLLOWING TREATMENT WITH HIGHER DOSES OF METHOTREXATE

Clinical Situation	Laboratory Findings	Leucovorin Dosage and Duration
Normal Methotrexate Elimination	Serum methotrexate level approximately 10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and less than 0.2 micromolar at 72 hours.	15 mg PO, IM or IV q 6 hours for 60 hours (10 doses starting at 24 hours after start of methotrexate infusion).
Delayed Late Methotrexate Elimination	Serum methotrexate level remaining above 0.2 micromolar at 72 hours, and more than 0.05 micromolar at 96 hours after administration.	Continue 15 mg PO, IM or IV q six hours, until methotrexate level is less than 0.05 micromolar.
Delayed Early Methotrexate Elimination and/or Evidence of Acute Renal Injury	Serum methotrexate level of 50 micromolar or more at 24 hours, or 5 micromolar or more at 48 hours after administration, OR; a 100% or	150 mg IV q three hours, until methotrexate level is less than 1 micromolar; than 15 mg IV q three hours, until methotrexate level is

Clinical Situation	Laboratory Findings	Leucovorin Dosage and Duration
	greater increase in serum creatinine level at 24 hours after methotrexate administration (e.g., an increase from 0.5 mg/dL to a level of 1 mg/dL or more).	less than 0.05 micromolar.

Psoriasis:

Recommended starting dose schedule:

- Weekly single intramuscular or intravenous dose schedule: 10 to 25 mg per week until adequate response is achieved.

Dosages in each schedule may be gradually adjusted to achieve optimal clinical response; 25 mg/week should not ordinarily be exceeded.

Once optimal clinical response has been achieved, the dosage schedule should be reduced to the lowest possible effective dose and to the longest possible rest period.

Rheumatoid Arthritis:

Recommended starting dosage schedule:

Dosages may be gradually adjusted to achieve optimal clinical response, but not ordinarily to exceed a total weekly dose of 20 mg.

Therapeutic response usually begins within 3 to 6 weeks and the patient may continue to improve for another 12 weeks or more. Upon achieving the therapeutically desired result, dosage should be reduced gradually to the lowest possible effective maintenance dose. The optimal duration of therapy is unknown; limited data from long-term studies indicate that the initial clinical improvement is maintained for at least 2 years with continued therapy.

Special Populations

Renal Impairment: Methotrexate is excreted to a significant extent by the kidneys, thus in patients with renal impairment the health care provider may need to adjust the dose to prevent accumulation of drug. The table below provided recommended starting doses in renally impaired patients; dosing may need further adjustment due to wide inter subject pK variability. Methotrexate Injection, USP is contraindicated in patients with severe renal impairment (see **CONTRAINDICATIONS**).

Table 5: Dose Adjustments in Patients with Renal Insufficiency

Creatinine Clearance (mL/min)	% Standard Dose to Administer
>80	Full Dose
80	75
60	63
50	56
<50	Use alternative therapy

Pediatrics (<18 years of age): Safety and effectiveness in pediatric patients have not been

established, other than in cancer chemotherapy (see **WARNINGS AND PRECAUTIONS: Special Populations, Pediatrics**).

Geriatrics (≥65 years of age): Due to diminished hepatic and renal function as well as decreased folate stores in elderly population, relatively low doses (especially in rheumatoid arthritis and psoriasis indications) should be considered and these patients should be closely monitored for early signs of toxicity. See **Table 5** for reduced doses in oncology patients with renal impairment.

Missed Dose

If a scheduled dose is missed, contact your doctor for instructions.

Administration

Dilution:

Methotrexate Injection, USP may be diluted with any of the solutions for IV infusion listed below in a concentration range of 0.4 mg/mL to 2 mg/mL. Dilutions should be used within 24 hours if kept at room temperature. Unused solution should be discarded after this time in order to avoid risk of microbial contamination.

Solutions:

0.9% Sodium Chloride Injection

5% Dextrose Injection

4% Dextrose and 0.18% Sodium Chloride Injection

Ringer's Injection

Since methotrexate is poorly soluble in acid media, use of potassium chloride solution or administration through the same line is not advisable.

If a preservative-free diluent is used, the solution should be used immediately because of the possibility of microbial growth. It is advisable to protect diluted solutions from light.

Due to the number of brands available, stability data of methotrexate in plastic syringes and bags are not available.

Methotrexate injection does not contain a preservative and is for single-use only. Unused product should be discarded due to the possibility of microbial growth.

Incompatibilities: Other drugs should not be mixed with methotrexate in the same infusion bottle. Methotrexate has been reported to be incompatible with cytarabine, fluorouracil, and prednisolone sodium phosphate; however, its incompatibility with fluorouracil has been questioned and subsequent studies documented in the literature indicate that methotrexate and cytarabine are physically and chemically stable in intravenous admixtures over a range of concentrations and in a variety of typical vehicles. A mixture of methotrexate with cytarabine and hydrocortisone sodium succinate in various infusion fluids has been reported to be visually compatible for at least 8 hours at 25°C, although precipitation did not occur on storage for several days. In general, compatibility of any medicinal product admixed with Methotrexate

Injection, USP must be assured prior to patient administration.

Contact with acidic solutions should be avoided since Methotrexate Injection, USP is sparingly soluble in acid media and precipitation may occur (see **WARNINGS AND PRECAUTIONS** for clinical incompatibilities).

OVERDOSAGE

Overdose with methotrexate has generally occurred with oral and intrathecal administration, although intravenous and intramuscular overdose have also been reported.

Discontinue or reduce dosage at the first sign of ulceration or bleeding, diarrhea, or marked depression of the hematopoietic system. Leucovorin is indicated to diminish the toxicity and counteract the effect of overdoses of methotrexate. Leucovorin administration should begin as promptly as possible. As the time interval between methotrexate administration and leucovorin initiation increases, the effectiveness of leucovorin in counteracting toxicity decreases. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.

In cases of massive overdose, hydration and urinary alkalinization may be necessary to prevent the precipitation of methotrexate and/or its metabolites in the renal tubules. Generally, neither standard hemodialysis nor peritoneal dialysis has been shown to improve methotrexate elimination. However, effective clearance of methotrexate has been reported with acute, intermittent hemodialysis using a high-flux dialyzer.

There are published case reports of intravenous carboxypeptidase G2 treatment to hasten clearance of methotrexate in cases of overdoses.

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Methotrexate is a folate antagonist.

Methotrexate inhibits dihydrofolate reductase (DHFR), the enzyme that reduces folic acid to tetrahydrofolic acid. Tetrahydrofolate must be regenerated via the DHFR-catalyzed reaction in order to maintain the intracellular pool of tetrahydrofolate one-carbon derivatives for both thymidylate and purine nucleotide biosynthesis. The inhibition of DHFR by folate antagonists (methotrexate) results in a deficiency in the cellular pools of thymidylate and purines and thus in a decrease in nucleic acid synthesis. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication.

Methotrexate is most active against rapidly multiplying cells, because its cytotoxic effects occur primarily during the S phase of the cell cycle. Since cellular proliferation in malignant tissues is greater than in most normal tissues, methotrexate may impair malignant growth without irreversible damage to normal tissues. As a result, actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to DHFR inhibition effects of methotrexate.

The cytotoxicity of methotrexate results from three important actions: inhibition of DHFR, inhibition of thymidylate synthase, and alteration of the transport of reduced folates. The affinity of DHFR to methotrexate is far greater than its affinity for folic acid or dihydrofolic acid, therefore, large doses of folic acid given simultaneously will not reverse the effects of methotrexate. However, Leucovorin calcium, a derivative of tetrahydrofolic acid may block the effects of methotrexate if given shortly after the antineoplastic agent. Methotrexate in high doses, followed by leucovorin rescue, is used as a part of the treatment of patients with non-metastatic osteosarcoma.

The original rationale for high-dose methotrexate therapy was based on the concept of selective rescue of normal tissues by leucovorin. More recent evidence suggests that high dose methotrexate may also overcome methotrexate resistance caused by impaired active transport, decreased affinity of dihydrofolic acid reductase for methotrexate, increased levels of dihydrofolic acid reductase resulting from gene amplification, or decreased polyglutamination of methotrexate. The actual mechanism of action is unknown.

Methotrexate has immunosuppressive activity. This may be a result of inhibition of lymphocyte multiplication. The mechanisms of action in the management of rheumatoid arthritis of the drug are not known, although suggested mechanisms have included immunosuppressive and/or anti-inflammatory effects.

In psoriasis, the rate of production of epithelial cells in the skin is greatly increased over normal skin. This differential in proliferation rates is the basis for the use of methotrexate to control the psoriatic process.

Pharmacokinetics

Absorption: Methotrexate is generally completely absorbed following parenteral administration, and after intramuscular injection peak serum concentrations occur in 30 to 60 minutes.

Distribution: Methotrexate is widely distributed into body tissues with highest concentrations in the kidneys, gallbladder, spleen, liver and skin. Methotrexate in serum is approximately 50% protein-bound. After intravenous administration, the initial volume of distribution is approximately 0.18 L/kg (18% of body weight) and steady-state volume of distribution is approximately 0.4 to 0.8 L/kg (40% to 80% of body weight). Methotrexate does not penetrate the blood-cerebrospinal fluid barrier in therapeutic amounts when given parenterally.

Metabolism: At low doses, methotrexate does not appear to undergo significant metabolism; following high-dose therapy, methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms that can be converted back to methotrexate by hydrolase enzymes.

These polyglutamates act as inhibitors of dihydrofolate reductase and thymidylate syntheses. Small amounts of methotrexate polyglutamates may remain in tissues for extended periods. The retention and prolonged drug action of these active metabolites vary among different cells, tissues and tumours. A small amount of metabolism to 7-hydroxymethotrexate may occur at doses commonly prescribed. The aqueous solubility of 7-hydroxymethotrexate is 3 to 5 fold lower than the parent compound.

Excretion: Renal excretion is the primary route of elimination and is dependent upon dosage and route of administration. Total clearance averages 12 L/h, but there is wide interindividual variation. Excretion of single daily doses occurs through the kidneys in amounts from 80% to 90% within 24 hours. Repeated daily doses result in more sustained serum levels and some retention of methotrexate over each 24-hour period, which may result in accumulation of the drug within the tissues. The liver cells appear to retain certain amounts of the drug for prolonged periods even after a single therapeutic dose. Methotrexate is retained in the presence of impaired renal function and may increase rapidly in the serum and in the tissue cells under such conditions. Methotrexate does not penetrate the blood-cerebrospinal fluid barrier in therapeutic amounts when given parenterally. High concentrations of the drug, when needed, may be attained by direct intrathecal administration.

The terminal half-life reported for methotrexate is approximately 3 to 10 hours for patients receiving treatment for psoriasis, rheumatoid arthritis or low dose antineoplastic therapy (less than 30 mg/m²). For patients receiving high doses of methotrexate, the terminal half-life is 8 to 15 hours.

Methotrexate clearance rates vary widely and are generally decreased at higher doses.

Special Populations and Conditions

Nursing Women: Methotrexate has been detected in human breast milk and is contraindicated during breast-feeding. The highest breast milk to plasma concentration ratio reached was 0.08:1.

Pediatrics: In pediatric patients receiving methotrexate for acute lymphocytic leukemia (6.3 to 30 mg/m²), the terminal half-life has been reported to range from 0.7 to 5.8 hours.

Geriatrics: The clinical pharmacology of methotrexate has not been well studied in older individuals. Due to diminished hepatic and renal function as well as decreased folate stores in this population, relatively low doses (especially in RA and psoriasis indications) should be considered and these patients should be closely monitored for early signs of toxicity.

Renal Impairment: Since the renal excretion of methotrexate is the primary route of elimination with 80% to 90% of the single daily doses of methotrexate excreted through the kidneys within 24 hours, methotrexate is retained in the presence of impaired renal function and may increase rapidly in the serum and in the tissue cells under such conditions, thus in patients with renal impairment the health care provider may need to adjust the dose to prevent accumulation of drug.

Hepatic Impairment: Hepatic excretion of methotrexate is a minor route of elimination.

However, the liver cells appear to retain certain amounts of the drug for prolonged periods even after a single therapeutic dose. Special caution is indicated in the presence of pre-existing liver damage or impaired hepatic function.

STORAGE AND STABILITY

Keep in a safe place out of the reach of children.

Store Methotrexate Injection, USP vials between 15-25° C. Protect from light.

Unused preservative free products should be discarded due to the possibility of microbial growth.

It is recommended that the vial remains in the carton until time of use. The Methotrexate Injection, USP vial should be inspected for damage and visible signs of leaks. If there are signs of breakage or leakage from the vial, do not use. Incinerate the unopened package.

SPECIAL HANDLING INSTRUCTIONS

General: Individuals who have contact with anti-cancer drugs, or work in areas where these drugs are used, may be exposed to these agents in air or through direct contact with contaminated objects.

Safe Handling and Disposal:

Good medical practice will minimize exposure of persons involved with frequent handling of this drug as outlined below:

Handling:

1. Methotrexate has no vesicant properties and does not show acute toxicity on topical contact with the skin or mucous membranes. However, persons involved with handling cytotoxic drugs should avoid contact with skin and inhalation of airborne particles.
2. Preparation of antineoplastic solutions should be done in a vertical laminar flow hood (Biological Safety Cabinet - Class II).
3. Personnel preparing methotrexate solutions should wear PVC gloves, safety glasses and protective clothing such as disposable gowns and masks.
4. Personnel regularly involved in the preparation and handling of antineoplastics should have bi-annual blood examinations.

Disposal:

1. Avoid contact with skin and inhalation of airborne particles by use of PVC gloves and disposable gowns and masks.
2. All needles, syringes, vials and other materials for disposal which have come in contact with Methotrexate Injection, USP should be segregated in plastic bags, sealed and marked as hazardous waste. Incinerate at 1000°C or higher. Sealed containers may explode if a tight seal exists.

3. If incineration is not available, rinse all needles, syringes, tubing and other materials for disposal which have come in contact with methotrexate solutions with water and discard in the sewer system with running water.

Rinse vials with the appropriate quantity of water with the aid of a hypodermic syringe. Withdraw the solution and discard in the sewer system with running water. Dispose of rinsed equipment and vials in a safe manner.

Cleaning: Non-disposable equipment that has come in contact with Methotrexate Injection, USP may be rinsed with water and washed thoroughly with soap and water.

Spillage/Contamination: Wear gloves, mask and protective clothing. Place spilled material in an appropriate container (i.e. cardboard for broken glass) and then in a polyethylene bag; absorb remains with gauze pads or towels; wash area with water and absorb with gauze or towels again and place in bag; seal, double bag and mark as a hazardous waste. Dispose of waste by incineration or by other methods approved for hazardous materials. Personnel involved in clean up should wash with soap and water.

DOSAGE FORMS, COMPOSITION AND PACKAGING

- (1) **Methotrexate Injection, USP** is supplied in vials containing 50 mg, 1000 mg of Methotrexate (as the sodium salt) as follows:

25 mg/mL Methotrexate	50 mg / 2 mL* (contains no preservative)
25 mg/mL Methotrexate	1000 mg / 40 mL* (contains no preservative)

* Single use vials

2 mL vials include brown flip-off aluminum seals

40 mL vials include golden yellow flip-off aluminum seals

Vials are supplied in cartons.

Composition: Methotrexate Injection, USP is a sterile, isotonic solution containing:

Methotrexate 25mg/mL with 4.9 mg/mL Sodium Chloride in water for injection. Sodium Hydroxide and Hydrochloric acid are added as pH adjusters. Methotrexate Injection does not include any preservative and is for single-use only.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: Methotrexate

Chemical name: N-[4-[[[(2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid

Molecular formula and molecular mass: C₂₀H₂₂N₈O₅ (454.45 g/mol)

Structural formula:



Physicochemical properties:

Physical Form: A yellow to orange-brown crystalline powder. Contains not more than 12% water. Methotrexate is a mixture of 4-amino-10-methylfolic acid and closely related compounds and is equivalent to not less than 94.0% of C₂₀H₂₂N₈O₅ calculated on the anhydrous basis. The parenteral solution is prepared with the sodium salt, but potency is always expressed on the basis of the acid.

Solubility: Practically insoluble in water, chloroform, ether and alcohol, but freely soluble in dilute solutions of mineral acids, alkali hydroxides and carbonates.

DETAILED PHARMACOLOGY

Human Pharmacokinetics

Absorption:

Methotrexate is generally completely absorbed from parenteral routes of injection. After intramuscular injection, peak serum concentrations occur in 30 to 60 minutes.

Distribution:

After intravenous administration, the initial volume of distribution is approximately 0.18 L/kg (18% of body weight) and steady-state volume of distribution is approximately 0.4 to 0.8 L/kg (40% to 80% of body weight). Methotrexate competes with reduced folates for active transport across cell membranes by means of a single carrier-mediated active transport process. At serum concentrations greater than 100 micromolar, passive diffusion becomes a major pathway by which effective intracellular concentrations can be achieved. Methotrexate in serum is approximately 50% protein-bound. Laboratory studies demonstrate that it may be displaced from plasma albumin by various compounds including sulfonamides, salicylates, tetracyclines, chloramphenicol, and phenytoin.

Methotrexate does not penetrate the blood-cerebrospinal fluid barrier in therapeutic amounts when given parenterally. High cerebrospinal fluid concentrations of the drug may be attained by intrathecal administration.

In dogs, synovial fluid concentrations after oral dosing were higher in inflamed than uninflamed joints. Although salicylates did not interfere with this penetration, prior prednisone treatment reduced penetration into inflamed joints to the level of normal joints.

Metabolism:

After absorption, methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms which can be converted back to methotrexate by hydrolase enzymes. These polyglutamates act as inhibitors of dihydrofolate reductase and thymidylate syntheses. Small amounts of methotrexate polyglutamates may remain in tissues for extended periods. The retention and prolonged drug action of these active metabolites vary among different cells, tissues and tumours. A small amount of metabolism to 7-hydroxymethotrexate may occur at doses commonly prescribed. Accumulation of this metabolite may become significant at the high doses used in osteogenic sarcoma. The aqueous solubility of 7-hydroxymethotrexate is 3 to 5 fold lower than the parent compound.

Half-Life:

The terminal half-life reported for methotrexate is approximately three to ten hours for patients receiving treatment for psoriasis, rheumatoid arthritis or low-dose antineoplastic therapy (less than 30 mg/m²). For patients receiving high doses of methotrexate, the terminal half-life is eight to fifteen hours.

Excretion:

Renal excretion is the primary route of elimination and is dependent upon dosage and route of administration. With IV administration, 80% to 90% of the administered dose is excreted

unchanged in the urine within 24 hours. There is limited biliary excretion amounting to 10% or less of the administered dose. Enterohepatic recirculation of methotrexate has been proposed.

Renal excretion occurs by glomerular filtration and active tubular secretion. Non-linear elimination due to saturation of renal tubular reabsorption has been observed in psoriatic patients at doses between 7.5 and 30 mg. Impaired renal function, as well as concurrent use of drugs such as weak organic acids that also undergo tubular secretion, can markedly increase methotrexate serum levels. Excellent correlation has been reported between methotrexate clearance and endogenous creatinine clearance.

Methotrexate clearance rates vary widely and are generally decreased at higher doses. Delayed drug clearance has been identified as one of the major factors responsible for methotrexate toxicity. It has been postulated that the toxicity of methotrexate for normal tissues is more dependent upon the duration of exposure to the drug rather than the peak level achieved. When a patient has delayed drug elimination due to compromised renal function, a third space effusion, or other causes, methotrexate serum concentrations may remain elevated for prolonged periods.

The potential for toxicity from high-dose regimens or delayed excretion is reduced by the administration of leucovorin calcium during the final phase of methotrexate plasma elimination. Pharmacokinetic monitoring of methotrexate serum concentrations may help identify those patients at high risk for methotrexate toxicity and aid in proper adjustment of leucovorin dosing.

TOXICOLOGY

The acute toxicity (LD₅₀) of methotrexate in mice ranges from 65 to 70 mg/kg intravenously. In dogs, the intravenous dose of 50 mg/kg was lethal. The main targets after a single dose were the hemolymphopoietic system and gastrointestinal (GI) tract.

The acute oral toxicity (LD₅₀) in rats is 180 mg/kg; subcutaneously, it is 58 mg/kg. The tolerance to methotrexate in mice increased with age. The toxic effects after repeated administration of methotrexate were investigated in mice and rats. The main targets of methotrexate in the above animal species were the hemolymphopoietic system, GI tract, lung, liver, kidney, testes, and skin. The tolerance of mice to chronic methotrexate doses increased with age.

In a 22-month carcinogenicity study in rats that received methotrexate at doses of 0.1, 0.2 and 0.4 mg/kg/day, 5 days/week every other week, little or no effect of the drug was observed. It has been concluded that methotrexate is apparently remarkably free from toxic effects when otherwise lethal doses are administered utilizing an intermittent dosage schedule providing for a recovery period of 9 days. For example, daily oral doses of 0.4 mg/kg are lethal doses both in dogs and rats when administered for up to two weeks; when 0.5 mg/kg and 0.4 mg/kg doses, respectively, were administered daily five times a week every other week for three months to dogs and ten months to rats, they were found to be essentially without toxicity.

Methotrexate is often used clinically in doses that are nearly toxic and may cause severe depression of all blood cellular elements. Constant supervision is recommended and signs of gastrointestinal ulceration and bleeding, including bleeding from the mouth, bone marrow

depression, primarily of the white cell series and alopecia are indications of toxicity. In general, toxicity is in direct proportion to dose and exposure time to methotrexate.

Toxicity of methotrexate to the bone marrow and gastrointestinal epithelium is not so much dependent on dosage as on the duration of exposure of these organs to the drug and its extracellular (plasma) concentration. For bone marrow and gastrointestinal tract, the critical time factor has been defined as about 42 hours and the critical plasma concentration as $2 \times 10^{-8} \text{M}$. Both factors must be exceeded for toxicity to occur to these organs.

Doses of methotrexate resulting in plasma levels in excess of $2 \times 10^{-8} \text{M}$ circulating for greater than 42 hours will be toxic to both the bone marrow and gastrointestinal epithelium. This toxicity can be minimized by the appropriate administration of Leucovorin Calcium.

Methotrexate may be hepatotoxic, particularly at high dosage and with prolonged therapy. Liver atrophy, necrosis, cirrhosis, fatty changes and periportal fibrosis have been reported.

REFERENCES

Anti-neoplastic Chemotherapy

1. Cannon GW. Pulmonary Toxicity of Methotrexate. In: William S. Wilke eds. Methotrexate Therapy in Rheumatic Disease. Marcel Dekker, Inc. 270 Madison Ave., New York, N.Y. 10016. 1989; 243-260.
2. Martindale: The Extra Pharmacopoeia. 29th Edition. James E.F. Reynolds ed. London Pharmaceutical Press 1989.
3. Evans AE, D'Angelo GJ, and Mitus A. Central Nervous System Complications of Children with Acute Leukemia. An Evaluation of Treatment Methods. J Pediat. 1964; 6:94-96.
4. Hertz R, Lewis J Jr., and Lipsett MB. Five Years' Experience with the Chemotherapy of Metastatic Choriocarcinoma and Related Trophoblastic Tumours in Women. Amer J Ob Gyn. 1961; 82:631-640.
5. Li MC. Trophoblastic Disease: Natural History, Diagnosis and Treatment. Ann. Int. Med. 1971; 74:102-112.
6. Krivit W, et al. Induction of Remission in Acute Leukemia of Childhood by Combination of Prednisone and either 6-mercaptopurine or Methotrexate. J Pediat. 1966; 68:965-968.
7. Acute Leukemia Group B.: Acute Lymphocytic Leukemia in Children. JAMA. 1969; 207:923-928.
8. Burchenal JH. Chemotherapy for Leukemia. Postgrad. Med. 1970; 48:164-168.
9. Ziegler JL, et al. Treatment of Burkitt's Tumour with Cyclophosphamide. Cancer. 1970; 26:474-484.
10. Hryniuk WM and Bertino JR. Treatment of Leukemia with Large Doses of Methotrexate and Folinic Acid: Clinical Biochemical Correlates. J Clin Invest. 1969; 48:2140-2155.
11. Hersh EM, Wong VG, Henderson ES, and Freireich EJ. Hepatotoxic Effects of Methotrexate. Cancer. 1966; 19:600-606.
12. Dixon RL, Henderson ES, and Rall DP. Plasma Protein Binding of Methotrexate and its Displacement by Various Drugs. Fed. Proc. 1965; 24:454.
13. Pitman SW and Frei E. Weekly Methotrexate-Calcium Leucovorin rescue: Effect of alkalinization on nephrotoxicity: Pharmacokinetics in the CNS; and use in CNS Non-Hodgkin's lymphoma. Cancer Treat Repts. 1977; 61(4):695-701.
14. Rooney TW, Furst De. Comparison of toxicity in Methotrexate (MTX) treated rheumatoid arthritis (RA) patients also taking aspirin (ASA) or other NSAID. Abstract. Arthritis Rheum 29 Suppl 4:S76.
15. Aherne et al. Br Med J. 1978; 1: 1097-1099.

16. Freisheim JH, Matthews DA. Dihydrofolate Reductases. Folate Antagonists as Therapeutic Agents. Academic Press Inc. 1984; 1:70-73.
17. DeVita Jr. LVT, Hellman S, Rosenberg SA. Clinical features of low-grade T-cell lymphomas. Cancer. Principles and Practice of Oncology. 4th. Ed. J.B. Lippincott Co., Philadelphia. pp. 1930-1935.
18. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, Ayala AG, Shuster JJ, Abelson HT, Simone JV, Vietti TJ. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Eng J Med. 1986; 314(25):1600-1606.
19. Stark AN, Jackson G, Carey PJ, Arfeen S, Proctor SJ. Severe renal toxicity due to intermediate-dose Methotrexate. Department of Haematology, Royal Victoria Infirmary, Newcastle-upon-Tyne.
20. Evans WE, Christensen ML. Drug interactions with Methotrexate. J Rheumatol (Canada). 1985; Suppl 12 12:15-20.
21. Chabner BA, Collins JM. Cancer chemotherapy principles and practice. Philadelphia: Lippincott, 1990; 449-464.
22. Nyfors A. Benefits and adverse drug experiences during long-term Methotrexate treatment of 248 psoriatics.

Psoriasis Chemotherapy

23. Roenigk HH Jr, Maibach HI, and Weinstein GD. Use of Methotrexate in Psoriasis. Arch Derm. 1972; 105:363-365.
24. Roenigk HH Jr, Bergfeld WF, and Curits GH. Methotrexate for Psoriasis in Weekly Oral Doses. Arch Derm. 1969; 99:86-93.
25. Rees RB, Bennett JH, Maibach HI, and Arnold HL. Methotrexate for Psoriasis. Arch Derm. 1971; 103:33-38.
26. Roenigk HH Jr, Maibach HI, and Weinstein GD. Methotrexate Therapy for Psoriasis. Arch Derm. 1973; 108:35.
27. Weinstein GD. Methotrexate for Psoriasis. JAMA. 1973; 225:412.
28. McDonald CJ and Bertino JR. Parenteral Methotrexate in Psoriasis. Arch Derm. 1969; 100:655-668.
29. Weinstein GD. Methotrexate for Psoriasis. Dermatology Digest. 1973; 12:49-53.
30. Weinstein GD and Velasco J. Selective Action of Methotrexate on Psoriatic Epidermal Cells. J of Investigative Dermatology. 1972; 59:121-127.
31. Coe RO and Bull FE. Cirrhosis Associated with Methotrexate Treatment of Psoriasis. JAMA. 1968; 206:1515-1520.

32. Weinstein CD, et al. Cooperative Study. Psoriasis-Liver Methotrexate Interactions. Arch Derm. 1973; 108:36-42.
33. Pearce HP and Wilson BB. Erosion of psoriatic plaques: An early sign of Methotrexate toxicity. Am Acad Dermatol. 1996;35:835-838.

NSAID Interactions

34. Adams JD and Hunter GA. Drug interaction in psoriasis. Aust J Derm. 1976; 17:3940.
35. Bloom EJ et al. Delayed clearance (CL) of Methotrexate (MTX) associated with antibiotics and anti-inflammatory agents. Abstract, Clin Res. 1986; 34, No. 2:560A.
36. Daly H. et al. Interaction between Methotrexate and non-steroidal anti-inflammatory drugs. Lancet. 1986; 557.
37. Daly H, et al. Methotrexate toxicity precipitated by azapropazone. Br J Derm. 1986; 114:733-735.
38. Doolittle GC, et al. Early-onset pancytopenia in two patients with rheumatoid arthritis receiving low-dose Methotrexate. Abstract 15C, Art. Rheum 1987; 30:S19, 1 Suppl.
39. Ellison NM, and Servi RJ. Acute renal failure and death following sequential intermediate-dose Methotrexate and 5-FU: A possible adverse effect due to concomitant Indomethacin administration. Cancer Treat Reps. 1985; 69(3):342-343.
40. Gabrielli A, et al. Methotrexate and non-steroidal anti-inflammatory drugs. Letter, Br Med J. 1987; 294:776.
41. Maiche AI. Acute renal failure due to concomitant action of Methotrexate and Indomethacin. Letter, Lancet. 1986; 1390.
42. Mandel MA. The synergistic effect of salicylates on Methotrexate toxicity. Plastic and Reconstructive Surg. 1976; 733-737.
43. Singh RR, et al. Fatal interaction between Methotrexate and Naproxen. Letter, Lancet. 1986; 1390.
44. Thyss A, et al. Clinical and pharmacokinetic evidence of a life-threatening interaction between Methotrexate and Ketoprofen. Lancet. 1986; 256-258.

Interaction with Radiotherapy

45. Turner SL, et al. Radical external beam radiotherapy of r333 squamous carcinomas of the oral cavity-Evaluation of the late morbidity and a watch policy for the clinically negative neck. Radiotherapy & Oncology. 1996;41:21-9.

Hemodialysis

46. Wall SM, et al. Effective clearance of Methotrexate using high-flux hemodialysis membranes. *Am J Kidney Dis.* 1996; 28(6):846-854.

General

47. Kremer JM, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. *Arthritis & Rheumatol.* 1994; 37(3):316-328.
48. Goodman TA, et al. Methotrexate: adverse reactions and major toxicities. *Rheumatic Disease Clinics of North America.* 1994; 20(2):513-28.
49. Tett SE, et al. Use of Methotrexate in older patients. A risk-benefit assessment. *Drugs & Aging.* 1996; 9(6):458-71.
50. Said S, et al. Systemic treatment: Methotrexate. *Clinics in Dermatology.* 1997; 15(5):781-97.
51. Evans WE, et al. *Applied Pharmacokinetics: Principles of therapeutic drug monitoring*, 3rd ed. Applied Therapeutics, Inc. Vancouver WA, 1992.
52. Green JA, et al. Drug interactions with cytotoxic agents. *Cancer Topics.* 1990; 7(11): 126-128.
53. Nierenberg W, et al. Toxic reaction to Methotrexate in a patient receiving penicillin and furosemide: a possible interaction. *Arch-Dermatol.* 1983; 119(6): 449-50.
54. Squire EN, et al. Unexpected adverse effects of Methotrexate (MTX) when used in the treatment of steroid-dependent asthma. *Ann Allergy-Asthma-Immunol.* 1996; 76(1):106 (Abs).
55. Glynn Barnhart AM, et al. Effect of low-dose Methotrexate on the deposition of glucocorticoids and theophylline. *J Allergy Clin Immunol.* 1991; 88(2):180-86.
56. Glynn Barnhat AM, et al. Effect of Methotrexate on prednisolone and theophylline pharmacokinetics. *Pharmacotherapy.* 1990; 10(3):255.
57. Yokoo H, Nakazato Y, Harigaya Y, et.al. Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report. *Acta Neuropathol.* 2007;114:425-430.
58. Worthley S, McNeil J. Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis. *J Rheumatol.* 1995;22:335-337.
59. Renard D, Westhovens R, Vandenbussche E, et.al. Reversible posterior leukoencephalopathy during oral treatment with methotrexate. *J Neurol.* 2004;251:226-228.
60. Raghavendra S, Nair MD, Chemmanam T, et.al. Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. *Eur J Neurol.* 2007;14:309-314.

61. Electronic communication from Yasuo Sugano, Labeling Group, PV Dept. Medical Affairs, WKK; 01 August 2008.
62. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systemic review of the literature. *Ann Rheum Dis.* 2009;68:1094-1099.
63. ^{Pr}Methotrexate (Methotrexate Tablets USP, Methotrexate Injection USP) Product Monograph. ©T.M. Wyeth, Pfizer Canada Inc., Licensee. Date of Revision: December 13, 2016. Submission Control Number: 186635.
64. ^{Pr}pms-Methotrexate (Methotrexate Tablets USP) Product Monograph, Date of Revision: August 24, 2017. Submission Control Number: 205553.
65. ^{Pr} Methotrexate Injection USP, Product Monograph. Pfizer Canada Inc., July 8, 2019, control no.: 224776.

PART III: CONSUMER INFORMATION

PrMETHOTREXATE INJECTION, USP
Unpreserved

25 mg/mL methotrexate (as methotrexate sodium)
(Sterile Solution)

Read this carefully before you start taking Methotrexate Injection, USP. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about Methotrexate Injection, USP.

ABOUT THIS MEDICATION

What the medication is used for:

Methotrexate Injection, USP belongs to a group of medicines known as antimetabolites. It is used in high doses to treat certain types of cancers, including breast cancer, Non-Hodgkin's lymphoma and leukemia. At lower doses, it may also be used to treat severe psoriasis and severe rheumatoid arthritis.

What it does: Methotrexate Injection, USP works by blocking an enzyme needed by body cells to live. This interferes with the growth of some cells, such as skin cells in psoriasis that are growing rapidly. In rheumatoid arthritis, Methotrexate Injection USP acts on the inflammatory cells that cause joint swelling. Methotrexate Injection, USP therapy is used to control psoriasis and rheumatoid arthritis but it will not cure them. In cancer, Methotrexate Injection, USP works by blocking an enzyme process in cancer cells so that they cannot grow. Some normal cells in the body may be affected as well.

When it should not be used:

Do not take Methotrexate Injection, USP if you:

- Are allergic to any component of the drug.
- Have severe kidney problems.
- Are on dialysis.
- Are pregnant. Methotrexate Injection, USP can cause harm to your unborn baby. Women of childbearing potential should not be started on Methotrexate Injection, USP until pregnancy is excluded.
- Are breast-feeding.
- Have psoriasis or rheumatoid arthritis and the following:
 - alcoholism (drink excessive alcohol)
 - chronic liver disease
 - immunodeficiency (resistance to infectious

- diseases is reduced)
- blood disorders
- Are going to receive a general anesthetic called nitrous oxide. It is also known as laughing gas.

What the medicinal ingredient is:

Methotrexate (as methotrexate sodium).

What the important nonmedicinal ingredients are:

Hydrochloric acid, sodium chloride, sodium hydroxide and water for injection.

What dosage forms it comes in:

Methotrexate Injection, USP 25 mg/mL comes in the following presentations:

25 mg/mL

50 mg / 2 mL (no preservative) as a single use vial
2 mL vials with brown flip-off aluminum seals

1000 mg / 40 mL (no preservatives) as a single use vial
40 mL vials golden yellow flip-off aluminum seals

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Methotrexate Injection, USP should be prescribed by a doctor who is experienced with the use of antimetabolite therapy.

- Methotrexate Injection, USP can cause serious toxic reactions which may result in death.
- Methotrexate Injection, USP can cause birth defect (deformed babies) or death of an unborn baby when used in pregnant women. Pregnant women with psoriasis or rheumatoid arthritis should not take Methotrexate Injection, USP.

Before you use Methotrexate Injection, USP, talk to your doctor or pharmacist if you have any of the following conditions:

- have or have had any unusual or allergic reaction to Methotrexate Injection, USP.
- are pregnant or planning to become pregnant. Methotrexate can cause birth defects (deformed babies) or death of an unborn baby. Both male and female patients must use effective birth control methods all the time while taking Methotrexate Injection, USP and a few months after the last dose of the drug. Methotrexate may cause sterility (infertility), which could be permanent. Be sure to discuss this with your doctor before taking Methotrexate Injection, USP. Tell your doctor right away if you think you have become pregnant while taking Methotrexate Injection, USP.
- are breast-feeding or plan to breast-feed.

IMPORTANT: PLEASE READ

Methotrexate may cause serious side effects. Do not breastfeed while you are taking the drug

- have kidney problems
- have kidney disease
- are dehydrated or have a lot of vomiting, diarrhea, or sweating
- have or have had liver problems, including hepatitis B or hepatitis C infection
- have lung problems
- have problem with your immune system, or infections
- have gastrointestinal problems such as vomiting, diarrhea, mouth sores or inflammation, ulcer, or colitis (ulcer of the intestines)
- have a skin disease
- have a neurologic disorder
- drink alcohol

Methotrexate Injection, USP increases sensitivity to sunlight. Avoid sun exposure and do not use a sunlamp while taking this drug.

Methotrexate can cause sudden bleeding in the lungs. This is called **Pulmonary alveolar haemorrhage**. If you suddenly spit or cough up blood you must go to the hospital right away. You will need emergency care. This occurs in patients with some existing health problems. Some examples are rheumatic disorder (such as pain in your joints) or vasculitis such as swelling in an artery or vein.

Precautions While Using This Medicine

- Do not take Methotrexate Injection, USP daily or more than the dose prescribed. Methotrexate can cause serious toxic reactions which may result in death.
- Do not drink alcohol.
- Do not drive a car or operate machinery until you know how Methotrexate Injection, USP affects you since the drug may cause dizziness and fatigue.
- Drink extra fluid to prevent kidney problems.
- Have regular blood tests to reduce the risk of infection or bleeding. Methotrexate can lower the number of white blood cells and there is an increased risk of infection or bleeding. Talk to your doctor if you need a vaccination. Live vaccines may cause severe infections. Live vaccines or contact with any individual who has had a live vaccination should be avoided, since your ability to fight an infection (immune system) is decreased while taking Methotrexate Injection, USP.

INTERACTIONS WITH THIS MEDICATION

Talk to your healthcare professional about all the

medicines you take or have recently taken, including any drugs, vitamins, minerals, natural supplements or alternative medicines. Methotrexate Injection, USP may interact with the following drugs:

Do not take METHOTREXATE INJECTION, USP if you are going to receive a general anesthetic called nitrous oxide. It is also known as laughing gas. When used together, they can cause:

- Myelosuppression (a condition in which the bone marrow cannot make enough blood cells),
- Mouth sores,
- Inflammation of the mouth,
- Inflammation of the kidneys
- Damage to the nervous system.

- Non-steroidal anti-inflammatory drugs (NSAIDs) and salicylate (acetylsalicylic acid or (ASA)
- Disease Modifying Antirheumatic drugs (DMARDs), such as gold, penicillamine, hydroxychloroquine, or sulfasalazine
- Drugs that may cause harm to the liver (leflunomide, azathioprine, sulfasalazine, retinoid)
- Phenylbutazone
- Phenytoin (to treat seizures)
- Probenecid
- Amphotericin B (may cause harm to kidneys)
- Certain antibiotics such as penicillins, tetracycline, vancomycin, nystatin, neomycin, trimethoprim/sulfamethoxazole, ciprofloxacin, pristinamycin, chloramphenicol
- Theophylline
- Mercaptopurine
- Folic acid or folinic acid
- Cytarabine and other chemotherapy agents
- Radiotherapy
- L-asparaginase, a drug used to treat cancer
- Proton pump inhibitors (PPI). They are drugs used to treat acid-related stomach problems. Some PPIs are omeprazole, esomeprazole, and pantoprazole.
- Pyrimethamine, an anti-parasitic drug
- Nitrous oxide, an inhaled gas used to prevent pain during medical procedures
- Amiodarone, a drug used to treat abnormal heart rhythms
- Sulfonylureas, drugs used to lower blood sugar levels, aminobenzoic acid, sulfonamides, also known as “sulfa drugs”
- Packed red blood cells, used for blood transfusions
- PUVA therapy, a type of ultraviolet light treatment for severe skin conditions
- Triamterene, a drug used to reduce blood pressure and decrease swelling

PROPER USE OF THIS MEDICATION

Methotrexate Injection is for single use only. Any unused product should be discarded by trained personnel.

Take Methotrexate Injection, USP only as directed by your doctor. Do not take more or less of it, and do not take it more often than your doctor ordered. The exact amount of medicine you need has been carefully worked out. Taking too much may increase the chance of side effects, while taking too little may not improve your condition. You should check with your doctor if you are not certain how to take the medication.

- **In most cases, Methotrexate Injection, USP is taken once weekly; the prescribed dose is taken on a single day of the week.**
- **In some cases, your healthcare professional may instruct you to take Methotrexate Injection, USP every 12 hours for 3 doses; you should only do this once a week, and should not take more than 3 doses each week.**
- **It should never be taken every day of the week. When used to treat psoriasis or rheumatoid arthritis. As well, in most cases of cancer, Methotrexate Injection, USP should not be taken every day of the week.**
- **Taking Methotrexate Injection, USP daily, or in a dose larger than prescribed can result in serious complications, often requiring hospitalization, and sometimes resulting in death. Taking even small doses of Methotrexate Injection, USP daily for less than a week can result in serious consequences, including death.**
- Select a day of the week when you are most likely to remember to take Methotrexate Injection, USP, and take it on that same day each week.
- Each time you refill your prescription, check to see whether the dose you need to take has changed.

Methotrexate Injection, USP is often given together with certain other medicines. If you are using a combination of medicines, make sure that you take each one at the proper time and do not mix them. Ask your doctor or pharmacist to help you plan a way to remember to take your medicines at the right times.

While you are using Methotrexate Injection, USP, your doctor may want you to drink extra fluids so that you will pass more urine. This will help the drug to pass from the body, and will prevent kidney problems and keep your kidneys working well.

If you vomit shortly after taking a dose of Methotrexate Injection, USP, check with your doctor. You will be

told whether to take the dose again or to wait until the next scheduled dose.

Usual dose:

The dose of Methotrexate Injection, USP will be different for different patients. The dose that is used may depend on a number of things, including what the medicine is being used for, the patient’s size, and whether or not other medicines are also being taken. If you are taking or receiving Methotrexate Injection, USP at home, follow your doctor's orders or the directions on the label. If you have any questions about the proper dose of Methotrexate Injection, USP, ask your doctor. The doctor may decrease your dose if you have problems with your kidneys.

Overdose:

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately

- Do this even if you have no signs of discomfort.

Missed dose:

- If you missed a scheduled dose, contact your doctor for instruction.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Along with their needed effects, medicines like Methotrexate Injection, USP can sometimes cause unwanted effects. Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer, such as leukemia. Discuss these possible effects with your doctor.

Methotrexate Injection, USP commonly causes nausea and vomiting. Even if you begin to feel ill, do not stop using this medicine without first checking with your doctor. Ask your doctor for ways to lessen these effects.

The most common side effects include:

- Upset stomach, stomach pain, vomiting, nausea, loss of appetite, dizziness, chills and fever, diarrhea or sores on lips or mouth
- A fall in the number of white blood cells. This may reduce your resistance to infection and increase your chances of cold sores, blood poisoning or swelling of blood vessels
- Tiredness (fatigue)

IMPORTANT: PLEASE READ

Less common side effects are:

- Headaches, hair loss, mood changes, confusion, ringing in the ears, sore eyes, skin rashes, increased sensitivity to sunlight or unexplained weight loss
- A fall in the number of other blood cells. This may increase your chances of bruising, bleeding or tiredness
- Damage to the lungs
- Harm to the unborn baby
- Convulsions

Rarely, Methotrexate Injection, USP can cause other side effects including:

- Liver damage, kidney damage, pain or difficulty urinating, lower back or side pain, blood in urine or stools, dark urine
- Fits, blurred vision, short term blindness
- Drowsiness, weakness
- Hoarseness
- Bloody vomit, black, tarry stools or pin-point red spots on the skin
- Reddening or whitening of the skin, acne, boils, itching yellow skin or eyes
- Impotence or loss of interest in sex, decreased fertility, abortion
- Diabetes, thinning of the bones, painful muscles and joints
- Low blood pressure
- Gastrointestinal ulcers

More rarely, it can cause:

- Skin rash and other skin disorders
- Cancer of lymph glands, sudden death
- Severe allergic reactions
- Leukoencephalopathy
- Damage to heart

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom / effect		Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
		Only if severe	In all cases	
Common	Diarrhea, vomiting, abdominal pain, or mouth ulcers			√
	Sore throat, fever, chills, or swelling of glands		√	
	Inflammation of the lungs: Persistent dry, non-productive cough, shortness		√	

	of breath and fever.			
Less common	Chest pain, cough, shortness of breath or fever			√
	Unusual bleeding or bruising			√
	Severe headaches			√
Rare	Signs of severe allergic reaction: Skin rash, itching, chest tightness, wheezing, dizziness, hives, faintness, rapid heartbeat, shortness of breath, and/or a swollen face, lips or tongue			√
	Pain or difficulty urinating, lower back or side pain, blood in urine or stools, dark urine		√	
	Yellow colour of eyes or skin			√
	Renal Failure/ kidney damage (inability of the kidneys to work properly): Swelling of the hands, ankles or feet. Nausea, vomiting. Blood in the urine. Changes in frequency or amount of urine.			√
Unknown	Gastrointestinal Related: Severe abdominal pain, tenderness, chills, fever, nausea, vomiting, extreme thirst, difficulty passing urine or bowel movement			√
	Central Nervous System Related: Behaviour changes,			√

decreased consciousness, headache, weakness, numbness, vision loss or double vision, seizures, vomiting, loss of memory			
DRESS (allergic reactions): Fever, rash, hives, swelling of eyes, lips or tongue			√
Pulmonary alveolar haemorrhage: suddenly spit or cough up blood			√

MORE INFORMATION

If you want more information about Methotrexate Injection, USP:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); or by calling Strides Pharma Canada Inc at 1-888-318-0234

This leaflet was prepared by
Strides Pharma Canada Inc.
1565, Boul. Lionel-Boulet
Varennes, Quebec
J3X 1P7

This is not a complete list of side effects. For any unexpected effects while taking Methotrexate Injection, USP, contact your doctor or pharmacist.

Revised on: October 14, 2021

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

HOW TO STORE IT

- Keep out of the reach and sight of children.
- Store it between 15°C to 25°C and away from heat.
- Protect from light. Avoid freezing Methotrexate Injection, USP.
- Methotrexate Injection, USP should not be used beyond the labeled expiry date.
- Do not keep outdated medicine or medicine no longer needed. Be sure that any discarded medicine is out of the reach of children.